Carlos E. Sanchez, MD, is an attending neurosurgeon in the Department of Neurosurgery and a principal investigator at the Cell Enhancement and Technologies for Immunotherapy Program at the George Washington University Cancer Center. He specializes in surgical care for patients with benign and malignant brain tumors. Fellowship trained in pediatric neurosurgery, Dr. Sanchez served as the director of skull base surgery at Children's National Hospital from 2018-2021 and specializes in caring for young adult and adult patients with neurosurgical conditions previously treated in childhood.
During his neurosurgery residency at the University of New Mexico, he pursued a CAST-certified fellowship in Neurocritical Care. He then completed a fellowship in Pediatric Neurosurgery at UCSD/Rady Children's Hospital under the guidance of Michael Levy, MD, Ph.D.
Dr. Sanchez completed his scientific training at Massachusetts General Hospital under the guidance of Bob Carter, MD, Ph.D., where he was a Ruth L. Kirschstein National Research Award Scholar. He subsequently was awarded a three-year NIH KL2 award through the Clinical and Translational Science Institute at Children's National, under the mentorship of Catherine Bollard, MD, MBChB. His scientific focus is the development of adoptive cell therapy technologies for brain tumors. Dr. Sanchez is a S.G.E. and serves as a consultant to the FDA, for the Cellular Tissue and Gene Therapies Advisory Committee (CTGTAC).
Beyond his clinical work, Dr. Sanchez serves on the Board of Advisors for Columbia University, Mailman School of Public Health and sits on the Health Equity Committee. His expertise and commitment to providing quality care and have also earned him recognition as a 2023 Washingtonian Top Doctor Award recipient.
